Autolus Therapeutics plc Receivables

Autolus Therapeutics plc's receivables stands at $28M as of March 2026. That compares with $65M in the prior-year period — down 57.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Autolus Therapeutics plc reported $28M in receivables versus $65M a year earlier — a 57.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $65M in the prior-year period — down 57.7% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Autolus Therapeutics plc's receivables evolved across reporting periods, while the comparison chart places AUTL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Autolus Therapeutics plc's reading of $28M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.